Advanced Cell Technology Inc.
381 Plantation Street
Biotech V
Worcester,
MA 01605
United States - Map
Phone: 508-756-1212
Fax: 508-756-4468
Web Site: http://www.advancedcell.com
| Index Membership: | N/A | | Sector: | | | Industry: | | | Full Time Employees: | 48 |
|
| Advanced Cell Technology, Inc., a biotechnology company, engages in the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. It primarily focuses on cellular reprogramming, reduced complexity program, and stem cell differentiation research programs. The company also develops adult stem cell-based products that are specifically targeted at therapies for heart and other cardiovascular diseases. It also plans to develop and commercialize products for use in the treatment of an array of chronic degenerative diseases and in regenerative repair of acute disease, such as trauma, infarction, and burns. The company has research and license agreements with University of Massachusetts, Wake Forest University, WiCell Research Institute, Inc., Kirin Beer Kabushiki Kaisha, and Start Licensing. It also has a joint venture agreement with CHA Biotech Co., Ltd. to develop human blood cells and other clinical therapies based on the companys proprietary hemangioblast cell technology. Advanced Cell Technology, Inc. is headquartered in Worcester, Massachusetts. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. William M. Caldwell IV, 61
Chairman, Chief Exec. Officer and Member of Compensation Committee |
N/A
| N/A | Dr. Robert P. Lanza M.D., 52
Chief Scientific Officer |
N/A
| N/A | Dr. Michael D. West Ph.D., 55
Consultant |
N/A
| N/A | Dr. Jonathan H. Dinsmore Ph.D., 47
Sr. VP of Regulatory and Clinical |
N/A
| N/A | Dr. R. Geoffrey Sargent Ph.D.,
Member of Sr. Scientific Team and Consultant |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-07
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.45% Nasdaq 
0.20%
Profile
